These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6298100)

  • 1. Renal vasodilation by converting enzyme inhibition. Role of renal prostaglandins.
    Oliver JA; Sciacca RR; Cannon PJ
    Hypertension; 1983; 5(2):166-71. PubMed ID: 6298100
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of prostaglandins in the renal response to angiotensin-converting enzyme inhibition and renal artery occlusion.
    van Leeuwen BH; Anderson WP; Johnston CI
    J Cardiovasc Pharmacol; 1983; 5(5):883-8. PubMed ID: 6195481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal PGE2 release may not be responsible for captopril-induced renal effects in anesthetized dogs.
    Satoh S; Hayashi M; Suzuki M; Hisa H; Kamijo T
    J Cardiovasc Pharmacol; 1982; 4(6):960-5. PubMed ID: 6185789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological evaluation in conscious dogs of factors involved in the renal vasodilator effect of captopril.
    Wong PC; Zimmerman BG; Kraft E; Kounenis G; Friedman P
    J Pharmacol Exp Ther; 1981 Dec; 219(3):646-50. PubMed ID: 7028950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal hemodynamic effects of captopril in anesthetized sodium-restricted dogs. Relative contributions of prostaglandin stimulation and suppressed angiotensin activity.
    Carmines PK; Rosivall L; Till MF; Navar LG
    Ren Physiol; 1983; 6(6):281-7. PubMed ID: 6359304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal adaptation to sodium deprivation. Effect of captopril in the rat.
    Mimran A; Jover B; Casellas D
    Am J Med; 1984 May; 76(5B):14-21. PubMed ID: 6328982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels.
    Johnston CI; Clappison BH; Anderson WP; Yasujima M
    Am J Cardiol; 1982 Apr; 49(6):1401-4. PubMed ID: 6122371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the kallikrein-kinin system in the renal effects of angiotensin-converting enzyme inhibition in anaesthetized dogs.
    Clappison BH; Anderson WP; Johnston CI
    Clin Exp Pharmacol Physiol; 1981; 8(5):509-13. PubMed ID: 6276063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of captopril-induced renal vasodilatation in anesthetized dogs after nonhypotensive hemorrhage.
    Wong PC; Zimmerman BG
    J Pharmacol Exp Ther; 1980 Oct; 215(1):104-9. PubMed ID: 7005423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
    Seymour AA; Sheldon JH; Smith PL; Asaad M; Rogers WL
    J Pharmacol Exp Ther; 1994 Apr; 269(1):263-70. PubMed ID: 8169834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graded regional vasodilation with converting enzyme inhibitors in conscious spontaneously hypertensive rats.
    Lappe RW; Todt JA; Wendt RL
    J Pharmacol Exp Ther; 1985 Dec; 235(3):651-6. PubMed ID: 3001271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses of renal, coronary and vertebral vasculatures to MC-838 and captopril in anesthetized dogs.
    Noguchi K; Kato T; Sunagawa R; Sakanashi M
    Pharmacology; 1987; 34(1):48-56. PubMed ID: 3033709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of extrarenal and intrarenal converting enzyme inhibition in renal vasodilator response to intravenous captopril.
    Wong PC; Zimmerman BG
    Life Sci; 1980 Oct; 27(14):1291-7. PubMed ID: 6255273
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased vascular responsiveness produced by angiotensin-converting enzyme inhibitors in the rat isolated kidney.
    Chiba S; Quilley CP; McGiff JC
    Hypertension; 1982; 4(3 Pt 2):80-5. PubMed ID: 6175573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of renal vasodilation with captopril: saralasin prevents the response in the DOCA-treated, salt-loaded rabbit.
    Hollenberg NK; Passan DR
    Life Sci; 1982 Jul; 31(4):329-34. PubMed ID: 6755124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct renal action of captopril (SQ 14225): dissociation of natriuretic and vascular actions in isolated perfused rat kidney.
    Ogihara T; Yasui T; Nakane H; Nakane Y; Satura T
    Am J Cardiol; 1982 Apr; 49(6):1511-2. PubMed ID: 7041588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and pharmacology of angiotensin converting enzyme inhibitors.
    Antonaccio MJ
    J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure.
    Faxon DP; Creager MA; Halperin JL; Bernard DB; Ryan TJ
    Am J Med; 1984 May; 76(5B):104-10. PubMed ID: 6203405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation.
    Kiowski W; van Brummelen P; Hulthén L; Amann FW; Bühler FR
    Clin Pharmacol Ther; 1982 Jun; 31(6):677-84. PubMed ID: 7042175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril.
    Textor SC; Tarazi RC; Novick AC; Bravo EL; Fouad FM
    Am J Med; 1984 May; 76(5B):29-37. PubMed ID: 6328984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.